The trajectory of companies tied to Sildenafil's past presents a challenging investment scenario . While the initial boom generated substantial gains, generic alternatives have significantly diminished sales . Investing in connected pharmaceutical companies now requires a discerning assessment of patent protection , evolving medical shifts , and th